Recursion Pharmaceuticals (RXRX) Total Debt (2020 - 2026)

Recursion Pharmaceuticals (RXRX) has 7 years of Total Debt data on file, last reported at $16.4 million in Q1 2026.

• Quarterly Total Debt fell 34.3% year-over-year to $16.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.4 million (down 34.3% YoY) and the FY2025 annual result came in at $18.7 million, down 32.03% from the prior year.
• Total Debt slipped to $16.4 million in Q1 2026, from $18.7 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $31.0 million in Q2 2024 to a low of $536000.0 in Q4 2022.
• A 5-year average of $12.4 million and a median of $8.8 million in 2023 frame the typical range for Total Debt.
• Annual changes were most pronounced in 2022 — Total Debt sank 93.78% — and 2024, when it surged 2586.58%.
• Tracing RXRX's Total Debt over 5 years: stood at $536000.0 in 2022, then soared by 113.06% to $1.1 million in 2023, then jumped by 2303.42% to $27.4 million in 2024, then tumbled by 32.03% to $18.7 million in 2025, then decreased by 11.84% to $16.4 million in 2026.
• The last three Total Debt figures came in at $16.4 million (Q1 2026), $18.7 million (Q4 2025), and $20.8 million (Q3 2025), per Business Quant data.